Treating heroin addicts. Blocking dosages and stimulation stabilization of opioidergic system

Heroin Addiction and Related Clinical Problems

Volumn 12, Issue 4, 2010, Pages 41-48

  Pacini, Matteo ^c   Maremmani, Angelo Giovanni Icro ^a,b   Rovai, Luca ^a   Rugani, Fabio ^a   Maremmani, Icro ^a,b,c  

^a UNIVERSITY OF PISA   (Italy)

^b Association for the Application of Neuroscientific Knowledge to Social Aims   (Italy)

^c G De Lisio   (Italy)

Author keywords

Addiction; Craving; Dependence; Normalization; Substance use disorder; Treatment duration

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE;

ARTICLE; AVERSION THERAPY; AVERSIVE BEHAVIOR; DETOXIFICATION; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GOLD STANDARD; HEROIN DEPENDENCE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

EID: 78651513108     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bauer L. O. (1992): Psychobiology of craving. In: Lowinson J. H., Ruiz P., Millman R. B., Langrod J. G. (Eds.): Substance Abuse A Comprehensive Textbook. Williams & Wilkins, Baltimore. pp.
2. Dole V. P., Nyswander M. E. (1967): Heroin Addiction: A Metabolic Disease. Arch Intern Med. 120 19-24.
3. Dole V. P., Nyswander M. E. (1983): Behavioral pharmacology and treatment of human drug abuse: methadone maintenance of narcotic addicts. In: Smith J. E., Lane J. D. (Eds.): The Neurobiology of opiate reward processes. Elsevier Biomedical Press, Amsterdam. pp. 211-233.
4. Dole V. P., Nyswander M. E., Kreek M. J. (1966): Narcotic Blockade. Arch Intern Med. 118 304-309.
5. Fantozzi F., Sinclair D. (2003): La ricaduta nell'alcol: un concetto vincente, ma in via di "estinzione"? In: Cibin M. (Ed.) La prevenzione della ricaduta nel trattamento della dipendenza da alcol. Franco Angeli Editore, Milano. pp.
6. Goldstein A. (1983): Some thoughts about endogenous opioids and addiction. Drug Alcohol Depend. 11 11-14.
7. Heinaelae P., Alho H., Kiianmaa K., Loennqvist J., Kuoppasalmi K., Sinclair J. D. (2001): Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence. A factorial double-blind placebocontrolled trial. J Clin Pharmacol. 21 287-292.
8. Maremmani I. (2008): When a New Drug Promotes the Integration of Treatment Modalities: Suboxone and Harm Reduction. Heroin Addict Relat Clin Probl. 10:(3) 5-12.
9. Maremmani I., Pacini M. (2003): Understanding the pathogenesis of drug addiction in order to implement a correct pharmacological intervention. Heroin Addict Relat Clin Probl. 5:(3) 5-12.
10. Maremmani I., Pacini M., Lubrano S., Lovrecic M. (2003): When 'enough' is still not 'enough'. Effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Addict Relat Clin Probl. 5:(1) 17-32.
11. Maremmani I., Pacini M., Lubrano S., Nardini R. (2006): Dove sono i pazienti resistenti?. Qualità delle terapie e controllo della malattia. Medicina delle Tossicodipendenze - Italian Journal of the Addictions. 48-49 61-69.
12. Maremmani I., Zolesi O., Aglietti M., Lubrano S., Placidi G. F. (1998): Neurotrasmettitori implicati nella fisiopatologia del craving e farmaci anticraving. Giornale Italiano di Psicopatologia. 4:(2) 288-305.
13. Nardini C. (1998): Counseling nella tossicodipendenza da eroina. Manuale di tecnica per l'orientamento del paziente. Gruppo SIMS, Pietrasanta.
14. Payte J. T., Zweben J. E., Martin J. (2003): Opioid maintenance treatment. In: Graham A. W., Schultz T. K., Mayo-Smith M. F., Ries R. K., Wilford B. B. (Eds.): Principles of Addiction Medicine. American Society of Addiction Medicine, Chevy Chase, MD. pp.
15. Payte T. J., Khuri E. T. (1993): Treatment duration and patient retention. In: Parrino M. W. (Ed.) State Methadone Treatment Guidelines. U.S. Department of Health & Human Services, Rockville,MD. pp. 119-124.
16. Presidenza Del Consiglio Dei Ministri (2007): Relazione annuale al parlamento sullo stato delle tossicodipendenze in Italia. Presidenza del Consiglio dei Ministri, Roma.
17. Ruden R., Byalick M. (1997): The craving brain. HarperCollins, New York.
18. Schifano F., Bargagli A. M., Belleudi V., Amato L., Davoli M., Diecidue R., Versino E., Vigna-Taglianti F., Faggiano F., Perucci C. A. (2006): Methadone treatment in clinical practice in Italy: need for improvement. Eur Addict Res. 12:(3) 121-127.
19. Smyth B., Hoffman V., Fan J., Hser Y. I. (2007): Years of potential life lost among heroin addicts 33 years after treatment. Prev Med. 44:(4) 369-374.
20. Tiffany S. T., Conklin C. A. (2000): A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction. 95 Suppl 2 S145-153.
21. Willner P., Scheel-Kruger J. (1991): The mesolimbic dopamine system: From motivation to action. John Wiley & Sons, New-York.
22. Wise R. A. (1983): Brain Neuronal Systems Mediating Reward Processes. Biomedical Press, Amsterdam.